Ab interno collagen implant for the treatment of uveitic glaucoma

Session Details

Session Title: Presented Poster Session: Glaucoma

Session Date/Time: Monday 07/09/2015 | 09:30-11:00

Paper Time: 10:20

Venue: Poster Village: Pod 4

First Author: : C.Sng SINGAPORE

Co Author(s): :    K. Barton              

Abstract Details

Purpose:

The XEN-45 gel stent is a novel ab interno collagen implant developed to lower the intraocular pressure (IOP) through a minimally invasive procedure. There are currently no published data on the clinical effectiveness of this implant. The purpose of our study is to evaluate the efficacy and safety of the XEN gel stent for the treatment of uveitic glaucoma.

Setting:

Uveitic glaucoma clinic in a tertiary ophthalmology centre (Moorfields Eye Hospital)

Methods:

We included 10 eyes of 10 patients with medically uncontrolled uveitic glaucoma who underwent XEN-45 gel stent implantation. Post-operatively, patients were assessed on days 1 and 7, and months 1, 3 and 6. The intraocular pressure (IOP), glaucoma medication use, Snellen's visual acuity (VA) and complications were assessed at each visit. The Wilcoxon signed rank test for non-parametric data was used for the analysis of IOP and glaucoma medications at baseline versus 6 months after the procedure.

Results:

Pre-operatively, the mean IOP was 30.3±10.6 mmHg and the mean number of hypotensive medications was 3.50±0.53. There was a significant decrease in IOP (17.5±6.2 mmHg) and the number of medications (1.17±1.17) 6 months post-operatively (p˂0.001). Further glaucoma filtration surgery was performed on 2 eyes for uncontrolled IOP less than 3 months after XEN-45 stent implantation. Early post-operative hypotony (IOP˂6 mmHg) occurred in 5 eyes, and all cases resolved within 2 weeks. Cataract progression with loss of ≥2 lines of VA was noted in 2 eyes, both of which underwent subsequent cataract surgery.

Conclusions:

The XEN-45 gel stent is generally an effective and safe treatment option for uveitic glaucoma. Infrequently, subsequent surgeries may be required for IOP control and cataract.

Financial Interest:

One of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, One of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented